Drug intelligence / Profile preview

ADP056

Development stage: Preclinical
Lead developer: Alector
Modality: Allosteric Modulators → Classical Binding Small Molecules → Small Molecules

Overview

ADP056 is a reelin modulator in preclinical development for the treatment of Alzheimer's disease. It is designed to block tau pathology and promote synaptic function by modulating reelin, a large secreted protein that regulates neuronal function and tau accumulation. Gain-of-function variants of reelin have been shown to protect against familial Alzheimer's disease by uncoupling amyloid and tau pathology; ADP056 aims to mimic or exceed these protective effects[1][3][4][8].

Targets

RELN (Reelin)

Beyond the preview

Go deeper on ADP056.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADP056.

Explore the full profile